top of page

VieCure and Clarified Precision Medicine Collaboration Now Deployed in Clinical Cancer Care, Already Delivering Positive Results in Accelerating Guidelines-based Precision Oncology Utilization

Jun 26, 2024

DENVER, CO and SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / VieCure, a cancer care company renowned for its artificial intelligence (AI) informatics, and clinical decision support platform, and Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options by combining expert medical provider review and underlying AI computational algorithms, are pleased to announce that their strategic collaboration is now live at Alabama Cancer Care (ALCC). This partnership, aimed at making precision medicine more accessible for patients and community oncologists, is already yielding significant positive results towards its goal of accelerating the utilization of guidelines-based precision oncology.

Since the launch of the collaboration, ALCC clinicians using the VieCure platform have been able to order ClarifiedSelect Reports with a single click. ClarifiedSelect Reports provide clinicians with genomically-informed treatment options based on tumor mutation panel results from any genomic testing provider, streamlining the order process and enhancing efficiency in the delivery of precision therapeutics. This seamless integration has empowered ALCC oncologists to make informed decisions based on each patient's molecular profiling data, ensuring that each patient receives tailored treatment options.

The collaboration's key achievements to date include:

One-click report ordering: Clinicians can now order ClarifiedSelect Reports directly through the VieCure platform with a single click, significantly reducing the time and effort required to obtain comprehensive molecular test interpretations.

Rapid response Times: Clarified Precision Medicine has demonstrated exceptional responsiveness, providing feedback on referrals in an average of 8 hours. This rapid turnaround has been instrumental in supporting timely and guideline-based precision medicine.

Enhanced treatment decisions: The timely feedback from Clarified has enabled greater adoption of precision oncology and reinforced precision oncology guidelines, allowing clinicians to modify therapy selection based on patients' unique circumstances. This has led to more personalized and effective treatment plans, ultimately improving patient outcomes.

Expert support: Oncologists have benefited from the ability to connect with Clarified Precision Medicine experts for in-depth discussions about molecular test results, further enhancing the quality of care provided to patients.

As explained by Ashvini Sengar MD, Hematologist and Medical Oncologist, Alabama Cancer Care, " Access to Clarified's precision oncology experts to help support decisions in complex cancer cases is particularly important today with advances in targeted therapies and immunotherapies. Getting timely feedback on approaches you can consider during busy clinics in community oncology is a tremendous advantage."

Howard McLeod , PharmD, FASCO, FCCP, Clarified co-founder and Personalized Medicine Coalition Board of Directors member, stated, "Our collaboration with VieCure is proving to be a game-changer in the field of precision oncology. Our ultimate goal is to make these advances more accessible to community oncologists and expand patient access to precision medicine. The integration of our expertise within the VieCure platform is now enabling ALCC clinicians to access the most up-to-date and accurate molecular profiling data quickly and efficiently, ultimately benefiting patients with more precise treatment options."

Dr. Fred Ashbury , Chief Scientific Officer at VieCure, added, "Cancer care is extremely complex, particularly with research advances identifying omics-guided treatments including targeted therapies and immunotherapy. VieCure's partnership with Clarified Precision Medicine facilitates timely access to their experts to support therapeutic decision making in busy community oncology practices to improve patient outcomes."

The VieCure-Clarified partnership exemplifies the power of collaboration in advancing cancer care. By combining VieCure and Clarified's AI-driven platforms with Clarified's expert insights, this partnership is making precision oncology more accessible, timely, and effective.

For more information about the VieCure and Clarified Precision Medicine collaboration, please visit viecure.com or clarifiedprecisionmedicine.com. You can also connect with VieCure on LinkedIn , Facebook , Twitter , Instagram , and YouTube , as well as find Clarified insights and updates on Instagram.

About Clarified Precision Medicine

Clarified Precision Medicine is the first scalable molecular tumor board with a combination of an AI-based platform with a medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelectâ„¢ and OncoGuardianâ„¢ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, please visit clarifiedprecisionmedicine.com or follow us on LinkedIn .


About VieCure

VieCure has developed a proprietary artificial intelligence informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The VieCureâ„¢ platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient's treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. VieCure was launched in 2016 and has contracted with leading community oncology cancer centers like Alabama Cancer Care (Tuscaloosa, Alabama), Oncology Care Partners, and several others including the American Oncology Network. The VieCure contracted cancer center network now includes more than 100 locations. Active implementation of the VieCure platform is occurring in network locations across the United States. For more information, please visit VieCure.com and connect with VieCure on LinkedIn , Facebook , Twitter , Instagram , and YouTube .

For More Information, Contact:VieCure, Inc.Hailey Hoguehailey.hogue@viecure.com

###

bottom of page